|
| Andhra Pradesh ~ India ~ International ~ City ~ Entertainment ~ Business ~ Bullion ~ Forex ~ Sports ~ Technology ~ Health ~ Features |
| Lung Cancer ~ Lung Cancer ~ Breast Cancer ~ Heart attack ~ All Health Topics |
|
Home
/ Health News / 2007 / October 2007 / October 17, 2007 Cancer drugs show promise to fight autoimmune diseases |
Shreya Life Sciences launches Oral-Recosulin
Worlds first Recombinant DNA Human Insulin Buccal Spray Solus Media
Sex, death form Oz Govts new anti-binge drinking campaign theme
A relationship between sex, death, and binge drinking forms the theme for the Australian Governments 20million-dollar campaign, which will target young drinkers as part of the National Binge Drinking Strategy. ANI
Moderate alcohol consumption beneficial for cardiovascular, cognitive health
Mild or moderate consumption of alcohol can have beneficial effects on the cardiovascular health and cognitive function of an individual, according to a new review. ANI
Scientists at the Childrens Hospital of Philadelphia have found that histone deacetylase (HDAC) inhibitors, drugs approved for treating cancers like lymphomas, have the potential to fight autoimmune diseases like sclerosis and rheumatoid arthritis.
London, October 17 : Scientists at the Children's Hospital of Philadelphia have found that histone deacetylase (HDAC) inhibitors, drugs approved for treating cancers like lymphomas, have the potential to fight autoimmune diseases like sclerosis and rheumatoid arthritis.
Dr. Wayne Hancock, a researcher behind the finding, has revealed in a report in Nature Medicine that autoimmune diseases are triggered when the immune system's T-cells go into overdrive, and attack the body's own cells.
Working with his colleagues, he has now discovered that HDAC inhibitors stimulate a specific class of immune cells called regulatory T-cells, which control the activity of other immune cells, including rogue T-cells.
They have found in tests on mice that HDAC inhibitors suppress inflammatory bowel disease and prevent rejection of heart and pancreatic grafts, reports the New Scientist.
Dr. Hancock thinks that HDAC inhibitors might have caused this effect by boosting both the number of regulatory T-cells and the amount of Foxp3, a messaging molecule they produce.
This surfeit of Foxp3 in turn suppresses the immune response of T-cells, he says.
ANI
